G-protein-linked receptors indirectly targeted by drugs

Question 1

Agonist via increasing dopamine at receptors D1 and D2 (possibly D3 and D4)

Answer 1

Stimulant at DAT and VMAT2 for improvement of ADHD. Antidepressant at DAT and NET for antidepressant and ADHD. MAO inhibitor reduces dopamine metabolism for antidepressant.

Question 2

Agonist via increasing serotonin at all serotonin receptors 5HT1A, 5HT2A; possibly 5HT2C, 5HT6, 5HT7

Answer 2

Antidepressant at SERT for depression and anxiety. MAO inhibitor for depression.

Question 3

Agonist via increasing norepinephrine at NET Beta2 and possibly Alpha2

Answer 3

Antidepressant and neuropathic pain at NET for depression, ADHD, and chronic pain when combined with SERT inhibition. MAO inhibitor reducing norepinephrine metabolism for depression.

Question 4

Agonist via increasing GABA at GABAa and GABAb.

Answer 4

Anticonvulsant at GABA GAT1 transporter for anticonvulsant; possibly anxiolytic, for chronic pain, for slow-wave sleep.

Question 5

Agonist via increasing acetylcholine at receptors M1 (possibly M2-M5)

Answer 5

Acetylcholinesterase inhibitor reducing acetylcholine metabolism for slowing Alzheimer’s disease progression.